esophageal squamous cell carcinoma (escc)

PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).

ZSH-2208 is a retinoic acid A analogue that inhibits tumour cell proliferation and survival through RARγ-TNFAIP3 and retinoid receptors.

Afatinib (BIBW 2992) oxalate is an irreversible, orally active bispecific inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFRwt, 0.4 nM for EGFRL858R, 10 nM for EGFRL858R T790M, and 14 nM for HER2. Afatinib oxalate can be used to study esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.

(R)-Afatinib ((R)-BIBW 2992), an isomer of Afatinib, is a potent, orally administered, irreversible inhibitor targeting the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM for EGFR wt, 0.4 nM for EGFR L858R, 10 nM for EGFR L858R T790M, and 14 nM for HER2, holding potential for research into esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer [1].

ERK-IN-6 (compound 6g) is a potent anti-proliferative agent against esophageal squamous cell carcinoma (ESCC), inducing apoptosis via the ERK pathway, with potential applications in ESCC research [1].

Xerophilusin B, isolated from Isodon xerophilus as an anticancer agent, demonstrates antiproliferative effects on esophageal squamous cell carcinoma (ESCC) cell lines. It induces G2 M cell cycle arrest and mediates apoptosis [1].